Search

Your search keyword '"Naidoo, Jarushka"' showing total 672 results
Start Over Author "Naidoo, Jarushka"
672 results on '"Naidoo, Jarushka"'

152. The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer.

Author

Bredin, Philip and Naidoo, Jarushka

Abstract

Systemic treatment options for patients with lung cancer have expanded in recent years, with a number of immunotherapeutic strategies now in our treatment armamentarium. Toxicity of and resistance to treatment hold a major stake in lung cancer morbidity and mortality. Herein, we summarise the background, current evidence and potential mechanisms underlying the role of the commensal gut microbiota in immunotherapy outcomes such as response and toxicity in patients with non-small cell lung cancer (NSCLC). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

153. Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses.

Author

Le, Thomas K., Kaul, Subuhi, Cappelli, Laura C., Naidoo, Jarushka, Semenov, Yevgeniy R., and Kwatra, Shawn G.

Subjects
IMMUNE checkpoint inhibitors, PEMBROLIZUMAB, URTICARIA, SKIN diseases, PROGRAMMED cell death 1 receptors, LICHEN planus, CELL receptors
Abstract

Dermatoses are common and potentially serious complications of programmed cell death receptor PD-1 immune checkpoint inhibitor (anti-PD-1 ICI) therapy. Understanding their incidence is necessary to support clinical awareness, diagnosis, and management. To examine the incidence and odds of reported non-cancerous dermatoses in the setting of anti-PD-1 ICI therapy. Cross-sectional study of anti-PD-1 (pembrolizumab or nivolumab) treated patients at a tertiary healthcare institution. Selected dermatologic events following immunotherapy were identified in the electronic medical record. Comparator arm were patients that developed these same dermatoses without receiving anti-PD-1 ICI therapy. There were 13.7% (254/1857) patients that developed one of 28 dermatoses. Compared with the general population, patients treated with anti-PD-1 had a greater risk for development of mucositis (OR 65.7, 95% CI 35.0–123.3), xerostomia (OR 11.9, 95% CI 8.4–16.8), pruritus (11.3, 95% CI 8.9–14.3), and lichen planus/lichenoid dermatitis (OR 10.7, 95% CI 5.6–20.7). We report the frequency of dermatoses encountered in the setting of ICI therapy, both common (pruritus, rash, vitiligo) and uncommon (scleroderma, urticaria). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

154. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.

Author

Naidoo, Jarushka, Vansteenkiste, Johan F., Faivre-Finn, Corinne, Özgüroğlu, Mustafa, Murakami, Shuji, Hui, Rina, Quantin, Xavier, Broadhurst, Helen, Newton, Michael, Thiyagarajah, Piruntha, and Antonia, Scott J.

Subjects
*CLINICAL trials, *NON-small-cell lung carcinoma, *HORMONE therapy, *PNEUMONIA, *IMMUNE checkpoint inhibitors
Abstract

• Grade 3/4 and fatal imAEs were uncommon with durvalumab after CRT. • Pneumonitis and thyroid disorders were the most common imAEs with this regimen. • ImAEs typically occurred within 3 months of durvalumab initiation. • In general, imAEs were well managed with appropriate clinical intervention. • Time elapsed between RT and randomization did not impact imAE incidence or severity. Immune-mediated adverse events (imAEs), including all-cause immune-mediated pneumonitis, were reported in approximately 25% of patients in the placebo-controlled, phase III PACIFIC trial of durvalumab monotherapy (for up to 12 months) in patients with unresectable, stage III NSCLC and no disease progression after concurrent chemoradiotherapy; only 3.4% of patients experienced grade 3/4 imAEs. With broad application of the PACIFIC regimen (consolidation durvalumab after chemoradiotherapy), now standard-of-care in this setting, there is a need to better characterize the occurrence of imAEs with this regimen. We performed descriptive, post-hoc, exploratory analyses to characterize the occurrence of imAEs (pneumonitis and non-pneumonitis) in PACIFIC in terms of: incidence, severity, and timing; clinical management and outcomes; and associations between the occurrence of imAEs and (1) all-cause AEs and (2) baseline patient, disease, and treatment characteristics. Any-grade immune-mediated pneumonitis (9.4%) and non-pneumonitis imAEs (10.7%) occurred infrequently and were more common with durvalumab versus placebo. Grade 3/4 immune-mediated pneumonitis (1.9%) and non-pneumonitis imAEs (1.7%) were uncommon with durvalumab, as were fatal imAEs (0.8%; all pneumonitis). The most common non-pneumonitis imAEs with durvalumab were thyroid disorders, dermatitis/rash, and diarrhea/colitis. Dermatitis/rash had the shortest time to onset (from durvalumab initiation), followed by pneumonitis; dermatitis/rash had the longest time to resolution, followed by thyroid disorders. Most patients with immune-mediated pneumonitis (78.4%) and non-pneumonitis imAEs (56.3%) had these events occur ≤ 3 months after initiating durvalumab. ImAEs were well managed with administration of systemic corticosteroids, administration of endocrine replacement therapy, and interruption/discontinuation of durvalumab. Time elapsed from completion of prior radiotherapy to trial randomization (<14 vs. ≥ 14 days) did not impact either incidence or severity of imAEs. Durvalumab had a manageable safety profile broadly irrespective of whether patients experienced imAEs. The risk of imAEs should not deter use of the PACIFIC regimen in eligible patients, as these events are generally well managed through appropriate clinical intervention. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

156. QIM21-090: The Expanding Role of an Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events

Author

Liang, Kai-li, primary, Tackett, Sean A., additional, Peterson, Valerie, additional, Patel, Tricia, additional, Turner, Michelle, additional, Sagorsky, Sarah, additional, Brahmer, Julie, additional, Hann, Christine, additional, Forde, Patrick, additional, Naidoo, Jarushka, additional, Marrone, Kristen A., additional, Ettinger, David, additional, Browner, Ilene S., additional, Lam, Vincent, additional, Hales, Russell K., additional, Voong, Khinh R., additional, and Feliciano, Josephine L., additional

Published
2021
Full Text
View/download PDF

157. A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors

Author

Shaikh, Fyza Y., primary, White, James R., additional, Gills, Joell J., additional, Hakozaki, Taiki, additional, Richard, Corentin, additional, Routy, Bertrand, additional, Okuma, Yusuke, additional, Usyk, Mykhaylo, additional, Pandey, Abhishek, additional, Weber, Jeffrey S., additional, Ahn, Jiyoung, additional, Lipson, Evan J., additional, Naidoo, Jarushka, additional, Pardoll, Drew M., additional, and Sears, Cynthia L., additional

Published
2021
Full Text
View/download PDF

159. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes

Author

Balaji, Aanika, primary, Hsu, Melinda, additional, Lin, Cheng Ting, additional, Feliciano, Josephine, additional, Marrone, Kristen, additional, Brahmer, Julie R, additional, Forde, Patrick M, additional, Hann, Christine, additional, Zheng, Lei, additional, Lee, Valerie, additional, Illei, Peter B, additional, Danoff, Sonye K, additional, Suresh, Karthik, additional, and Naidoo, Jarushka, additional

Published
2021
Full Text
View/download PDF

163. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

Author

Shankar, Bairavi, primary, Zhang, Jiajia, additional, Naqash, Abdul Rafeh, additional, Forde, Patrick M., additional, Feliciano, Josephine L., additional, Marrone, Kristen A., additional, Ettinger, David S., additional, Hann, Christine L., additional, Brahmer, Julie R., additional, Ricciuti, Biagio, additional, Owen, Dwight, additional, Toi, Yukihiro, additional, Walker, Paul, additional, Otterson, Gregory A., additional, Patel, Sandip H., additional, Sugawara, Shunichi, additional, and Naidoo, Jarushka, additional

Published
2020
Full Text
View/download PDF

164. 681 Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors

Author

Shaikh, Fyza, primary, White, James, additional, Gills, Joell, additional, Hakozaki, Taiki, additional, Corentin, Richard, additional, Routy, Bertrand, additional, Okuma, Yusuke, additional, Usyk, Mykhaylo, additional, Pandey, Abhishek, additional, Weber, Jeffrey, additional, Ahn, Jiyoung, additional, Naidoo, Jarushka, additional, Lipson, Evan, additional, Pardoll, Drew, additional, and Sears, Cynthia, additional

Published
2020
Full Text
View/download PDF

165. Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

Author

Ricciuti, Biagio, primary, Naqash, Abdul Rafeh, additional, Naidoo, Jarushka, additional, Sehgal, Kartik, additional, Miller, Adam, additional, Kehl, Kenneth, additional, Venkatraman, Deepti, additional, Sands, Jacob, additional, Lamberti, Giuseppe, additional, Recondo, Gonzalo, additional, Zhang, Jiajia, additional, Macherla, Shravanti, additional, Baig, Sameer, additional, Walker, Paul, additional, Rangachari, Deepa, additional, Gainor, Justin F., additional, Costa, Daniel B., additional, Rizvi, Naiyer, additional, Sholl, Lynette M., additional, Nishino, Mizuki, additional, Henick, Brian, additional, Farago, Anna F., additional, and Awad, Mark M., additional

Published
2020
Full Text
View/download PDF

167. 788 Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety and cerebrospinal fluid biomarkers

Author

Naidoo, Jarushka, primary, Schreck, Karisa, additional, Fu, Wei, additional, Hu, Chen, additional, Connolly, Roisin, additional, Santa-Maria, Cesar, additional, Lipson, Evan, additional, Holdhoff, Matthias, additional, Forde, Patrick, additional, Riemer, Joanne, additional, Barnes, Amanda, additional, Aygun, Nafi, additional, Kleinberg, Lawrence, additional, Redmond, Kristin, additional, Douville, Christopher, additional, Bettegowda, Chetan, additional, Venkatesan, Arun, additional, Grossman, Stuart, additional, and Brahmer, Julie, additional

Published
2020
Full Text
View/download PDF

169. Correction to: The gut microbiome, immune check point inhibition and immune‑related adverse events in non‑small cell lung cancer.

Author

Bredin, Philip and Naidoo, Jarushka

Abstract

This document is a correction notice for an article titled "The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer." The authors of the article, Philip Bredin and Jarushka Naidoo, initially published it without Open Access but later decided to make it an Open Access publication. The copyright of the article has been changed, and it is now distributed under the terms of the Creative Commons Attribution 4.0 International License. The original article has been corrected, and Springer Nature, the publisher, remains neutral regarding jurisdictional claims and institutional affiliations. [Extracted from the article]

Published
2024
Full Text
View/download PDF

170. Immune-related adverse events and the balancing act of immunotherapy.

Author

Conroy, Michael and Naidoo, Jarushka

Subjects
DRUG side effects, IMMUNE checkpoint inhibitors, IMMUNOTHERAPY, OPEN-ended questions
Abstract

The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

172. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

Author

Reuss, Joshua E, primary, Anagnostou, Valsamo, additional, Cottrell, Tricia R, additional, Smith, Kellie N, additional, Verde, Franco, additional, Zahurak, Marianna, additional, Lanis, Mara, additional, Murray, Joseph C, additional, Chan, Hok Yee, additional, McCarthy, Caroline, additional, Wang, Daphne, additional, White, James R, additional, Yang, Stephen, additional, Battafarano, Richard, additional, Broderick, Stephen, additional, Bush, Errol, additional, Brock, Malcolm, additional, Ha, Jinny, additional, Jones, David, additional, Merghoub, Taha, additional, Taube, Janis, additional, Velculescu, Victor E, additional, Rosner, Gary, additional, Illei, Peter, additional, Pardoll, Drew M, additional, Topalian, Suzanne, additional, Naidoo, Jarushka, additional, Levy, Ben, additional, Hellmann, Matthew, additional, Brahmer, Julie R, additional, Chaft, Jamie E, additional, and Forde, Patrick M, additional

Published
2020
Full Text
View/download PDF

174. Abstract CT249: A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO)

Author

Ileana Dumbrava, Ecaterina E., primary, Suarez-Almazor, Maria, additional, Painter, Jeane, additional, Johanns, Tanner M., additional, Dougan, Michael L., additional, Cappelli, Laura, additional, Wang, Yinghong, additional, Bingham, Clifton, additional, Gupta, Sarthak, additional, Warner, Blake M., additional, Rahma, Osama, additional, Naidoo, Jarushka, additional, Ott, Patrick A., additional, Hafler, David A., additional, Kluger, Harriet, additional, Khosroshahi, Arezou, additional, Naqash, Rafeh, additional, Chung, Lorinda, additional, Katsumoto, Tamiko R., additional, Kummar, Shivaani, additional, Tawbi, Hussein, additional, and Sharon, Elad, additional

Published
2020
Full Text
View/download PDF

177. Association between immune-related adverse events and clinical outcomes to PD-1/PD-L1 blockade in small cell lung cancer

Author

Ricciuti, Biagio, primary, Naqash, Abdul Rafeh, additional, Naidoo, Jarushka, additional, Sehgal, Kartik, additional, Miller, Adam, additional, Kehl, Kenneth, additional, Venkatraman, Deepti, additional, Sands, Jacob, additional, Lamberti, Giuseppe, additional, Recondo, Gonzalo, additional, Zhang, Jiajia, additional, Macherla, Shravanti, additional, Baig, Sameer, additional, Walker, Paul, additional, Rangachari, Deepa, additional, Gainor, Justin F., additional, Costa, Daniel B., additional, Rizvi, Naiyer, additional, Sholl, Lynette M., additional, Nishino, Mizuki, additional, Henick, Brian, additional, Farago, Anna F., additional, and Awad, Mark M., additional

Published
2020
Full Text
View/download PDF

179. Chronic immune checkpoint inhibitor pneumonitis

Author

Naidoo, Jarushka, primary, Cottrell, Tricia R, additional, Lipson, Evan J, additional, Forde, Patrick M, additional, Illei, Peter B, additional, Yarmus, Lonny B, additional, Voong, K Ranh, additional, Feller-Kopman, David, additional, Lee, Hans, additional, Riemer, Joanne, additional, Wang, Daphne, additional, Taube, Janis M, additional, Brahmer, Julie R, additional, Lin, Cheng Ting, additional, Danoff, Sonye K, additional, D'Alessio, Franco R, additional, and Suresh, Karthik, additional

Published
2020
Full Text
View/download PDF

180. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Kuderer, Nicole M, primary, Choueiri, Toni K, additional, Shah, Dimpy P, additional, Shyr, Yu, additional, Rubinstein, Samuel M, additional, Rivera, Donna R, additional, Shete, Sanjay, additional, Hsu, Chih-Yuan, additional, Desai, Aakash, additional, de Lima Lopes, Gilberto, additional, Grivas, Petros, additional, Painter, Corrie A, additional, Peters, Solange, additional, Thompson, Michael A, additional, Bakouny, Ziad, additional, Batist, Gerald, additional, Bekaii-Saab, Tanios, additional, Bilen, Mehmet A, additional, Bouganim, Nathaniel, additional, Larroya, Mateo Bover, additional, Castellano, Daniel, additional, Del Prete, Salvatore A, additional, Doroshow, Deborah B, additional, Egan, Pamela C, additional, Elkrief, Arielle, additional, Farmakiotis, Dimitrios, additional, Flora, Daniel, additional, Galsky, Matthew D, additional, Glover, Michael J, additional, Griffiths, Elizabeth A, additional, Gulati, Anthony P, additional, Gupta, Shilpa, additional, Hafez, Navid, additional, Halfdanarson, Thorvardur R, additional, Hawley, Jessica E, additional, Hsu, Emily, additional, Kasi, Anup, additional, Khaki, Ali R, additional, Lemmon, Christopher A, additional, Lewis, Colleen, additional, Logan, Barbara, additional, Masters, Tyler, additional, McKay, Rana R, additional, Mesa, Ruben A, additional, Morgans, Alicia K, additional, Mulcahy, Mary F, additional, Panagiotou, Orestis A, additional, Peddi, Prakash, additional, Pennell, Nathan A, additional, Reynolds, Kerry, additional, Rosen, Lane R, additional, Rosovsky, Rachel, additional, Salazar, Mary, additional, Schmidt, Andrew, additional, Shah, Sumit A, additional, Shaya, Justin A, additional, Steinharter, John, additional, Stockerl-Goldstein, Keith E, additional, Subbiah, Suki, additional, Vinh, Donald C, additional, Wehbe, Firas H, additional, Weissmann, Lisa B, additional, Wu, Julie Tsu-Yu, additional, Wulff-Burchfield, Elizabeth, additional, Xie, Zhuoer, additional, Yeh, Albert, additional, Yu, Peter P, additional, Zhou, Alice Y, additional, Zubiri, Leyre, additional, Mishra, Sanjay, additional, Lyman, Gary H, additional, Rini, Brian I, additional, Warner, Jeremy L, additional, Abidi, Maheen, additional, Acoba, Jared D., additional, Agarwal, Neeraj, additional, Ahmad, Syed, additional, Ajmera, Archana, additional, Altman, Jessica, additional, Angevine, Anne H., additional, Azad, Nilo, additional, Bar, Michael H., additional, Bardia, Aditya, additional, Barnholtz-Sloan, Jill, additional, Barrow, Briana, additional, Bashir, Babar, additional, Belenkaya, Rimma, additional, Berg, Stephanie, additional, Bernicker, Eric H., additional, Bestvina, Christine, additional, Bishnoi, Rohit, additional, Boland, Genevieve, additional, Bonnen, Mark, additional, Bouchard, Gabrielle, additional, Bowles, Daniel W., additional, Busser, Fiona, additional, Cabal, Angelo, additional, Caimi, Paolo, additional, Carducci, Theresa, additional, Casulo, Carla, additional, Chen, James L., additional, Clement, Jessica M, additional, Chism, David, additional, Cook, Erin, additional, Curran, Catherine, additional, Daher, Ahmad, additional, Dailey, Mark, additional, Dahiya, Saurabh, additional, Deeken, John, additional, Demetri, George D., additional, DiLullo, Sandy, additional, Duma, Narjust, additional, Elias, Rawad, additional, Faller, Bryan, additional, Fecher, Leslie A., additional, Feldman, Lawrence E., additional, Friese, Christopher R., additional, Fu, Paul, additional, Fu, Julie, additional, Futreal, Andy, additional, Gainor, Justin, additional, Garcia, Jorge, additional, Gill, David M., additional, Gillaspie, Erin A., additional, Giordano, Antonio, additional, Glace, (Mary) Grace, additional, Grothey, Axel, additional, Gulati, Shuchi, additional, Gurley, Michael, additional, Halmos, Balazs, additional, Herbst, Roy, additional, Hershman, Dawn, additional, Hoskins, Kent, additional, Jain, Rohit K., additional, Jabbour, Salma, additional, Jha, Alokkumar, additional, Johnson, Douglas B., additional, Joshi, Monika, additional, Kelleher, Kaitlin, additional, Kharofa, Jordan, additional, Khan, Hina, additional, Knoble, Jeanna, additional, Koshkin, Vadim S., additional, Kulkarni, Amit A., additional, Lammers, Philip E., additional, Leighton, John C., additional, Lewis, Mark A., additional, Li, Xuanyi, additional, Li, Ang, additional, Lo, K.M. Steve, additional, Loaiza-Bonilla, Arturo, additional, LoRusso, Patricia, additional, Low, Clarke A., additional, Lustberg, Maryam B., additional, Mahadevan, Daruka, additional, Mansoor, Abdul-Hai, additional, Marcum, Michelle, additional, Markham, Merry Jennifer, additional, Handy Marshall, Catherine, additional, Mashru, Sandeep H., additional, Matar, Sara, additional, McNair, Christopher, additional, McWeeney, Shannon, additional, Mehnert, Janice M., additional, Menendez, Alvaro, additional, Menon, Harry, additional, Messmer, Marcus, additional, Monahan, Ryan, additional, Mushtaq, Sarah, additional, Nagaraj, Gayathri, additional, Nagle, Sarah, additional, Naidoo, Jarushka, additional, Nakayama, John M., additional, Narayan, Vikram, additional, Nelson, Heather H., additional, Nemecek, Eneida R., additional, Nguyen, Ryan, additional, Nuzzo, Pier Vitale, additional, Oberstein, Paul E., additional, Olszewski, Adam J., additional, Owenby, Susie, additional, Pasquinelli, Mary M., additional, Philip, John, additional, Prabhakaran, Sabitha, additional, Puc, Matthew, additional, Ramirez, Amelie, additional, Rathmann, Joerg, additional, Revankar, Sanjay G., additional, Rho, Young Soo, additional, Rhodes, Terence D., additional, Rice, Robert L., additional, Riely, Gregory J., additional, Riess, Jonathan, additional, Rink, Cameron, additional, Robilotti, Elizabeth V., additional, Rosenstein, Lori, additional, Routy, Bertrand, additional, Rovito, Marc A., additional, Saif, M. Wasif, additional, Sanyal, Amit, additional, Schapira, Lidia, additional, Schwartz, Candice, additional, Serrano, Oscar, additional, Shah, Mansi, additional, Shah, Chintan, additional, Shaw, Grace, additional, Shergill, Ardaman, additional, Shouse, Geoffrey, additional, Soares, Heloisa P., additional, Solorzano, Carmen C., additional, Srivastava, Pramod K., additional, Stauffer, Karen, additional, Stover, Daniel G., additional, Stratton, Jamie, additional, Stratton, Catherine, additional, Subbiah, Vivek, additional, Tamimi, Rulla, additional, Tannir, Nizar M., additional, Topaloglu, Umit, additional, Van Allen, Eli, additional, Van Loon, Susan, additional, Vega-Luna, Karen, additional, Venepalli, Neeta, additional, Verma, Amit K., additional, Vikas, Praveen, additional, Wall, Sarah, additional, Weinstein, Paul L., additional, Weiss, Matthias, additional, Wise-Draper, Trisha, additional, Wood, William A., additional, Xu, Wenxin (Vincent), additional, Yackzan, Susan, additional, Zacks, Rosemary, additional, Zhang, Tian, additional, Zimmer, Andrea J., additional, and West, Jack, additional

Published
2020
Full Text
View/download PDF

182. Information Visualization Platform for Postmarket Surveillance Decision Support

Author

Spiker, Jonathan, primary, Kreimeyer, Kory, additional, Dang, Oanh, additional, Boxwell, Debra, additional, Chan, Vicky, additional, Cheng, Connie, additional, Gish, Paula, additional, Lardieri, Allison, additional, Wu, Eileen, additional, De, Suranjan, additional, Naidoo, Jarushka, additional, Lehmann, Harold, additional, Rosner, Gary L., additional, Ball, Robert, additional, and Botsis, Taxiarchis, additional

Published
2020
Full Text
View/download PDF

183. Comprehensive modeling of longitudinal circulating tumor DNA dynamics to predict clinical response to first-line immunotherapy and chemoimmunotherapy in advanced non-small cell lung cancer.

Author

Murray, Joseph Christopher, primary, Rhymee, Lamia, additional, Marrone, Kristen, additional, Naidoo, Jarushka, additional, Levy, Benjamin Philip, additional, Ferreira, Leonardo, additional, Rosner, Samuel, additional, Lanis, Mara, additional, Hann, Christine L., additional, Feliciano, Josephine Louella, additional, Lam, Vincent K., additional, Ettinger, David S., additional, Illei, Peter Bela, additional, Wang, Chenguang, additional, Brahmer, Julie R., additional, Forde, Patrick M., additional, Velculescu, Victor E., additional, Scharpf, Robert B., additional, and Anagnostou, Valsamo, additional

Published
2020
Full Text
View/download PDF

184. Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial.

Author

Yan, Melissa, primary, Durm, Greg Andrew, additional, Mamdani, Hirva, additional, Ernani, Vinicius, additional, Jabbour, Salma K., additional, Naidoo, Jarushka, additional, Hrinczenko, Borys, additional, Leal, Ticiana, additional, Feldman, Lawrence Eric, additional, Kloecker, Goetz H., additional, Fujioka, Naomi, additional, Fidler, Mary J., additional, and Hanna, Nasser H., additional

Published
2020
Full Text
View/download PDF

185. Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).

Author

Naidoo, Jarushka, primary, Vansteenkiste, Johan F., additional, Faivre-Finn, Corinne, additional, Özgüroğlu, Mustafa, additional, Murakami, Shuji, additional, Hui, Rina, additional, Quantin, Xavier, additional, Broadhurst, Helen, additional, Newton, Michael, additional, Dennis, Phillip A., additional, and Antonia, Scott Joseph, additional

Published
2020
Full Text
View/download PDF

186. A multidisciplinary immune-related toxicity (IR-Tox) program for immune-related adverse events: A two-year experience.

Author

Balaji, Aanika, primary, Zhang, Jiajia, additional, Suresh, Karthik, additional, Mammen, Jenna, additional, Melia, Joanna, additional, Kim, Amy K., additional, Berkenstock, Meghan, additional, Sander, Inbal, additional, Monroy-Trujillo, Jose Manuel, additional, Ostrow, Lyle Wilfred, additional, Riemer, Joanne, additional, Lipson, Evan J., additional, Forde, Patrick M., additional, Sharfman, William Howard, additional, Brahmer, Julie R., additional, Cappelli, Laura, additional, and Naidoo, Jarushka, additional

Published
2020
Full Text
View/download PDF

187. A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

Author

Ileana Dumbrava, Ecaterina Elena, primary, Suarez-Almazor, Maria E., additional, Painter, Jeane, additional, Johanns, Tanner, additional, Dougan, Michael L., additional, Cappelli, Laura, additional, Bingham, Clifton O., additional, Wang, Yinghong, additional, Gupta, Sarthak, additional, Warner, Blake M, additional, Rahma, Osama E., additional, Naidoo, Jarushka, additional, Ott, Patrick Alexander, additional, Hafler, David A, additional, Kluger, Harriet M., additional, Khosroshahi, Arezou, additional, Katsumoto, Tamiko R, additional, Kummar, Shivaani, additional, Sharon, Elad, additional, and Tawbi, Hussein Abdul-Hassan, additional

Published
2020
Full Text
View/download PDF

188. Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.

Author

Kozono, David E., primary, Sharon, Elad, additional, Le-Rademacher, Jennifer, additional, Twohy, Erin, additional, Zemla, Tyler J., additional, Wen, Yujia, additional, Watson, Mark, additional, Dib, Elie G., additional, Kirkwood, John M., additional, Lyman, Gary H., additional, Naidoo, Jarushka, additional, Nixon, Andrew B., additional, and Mittendorf, Elizabeth A., additional

Published
2020
Full Text
View/download PDF

189. Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response.

Author

Naidoo, Jarushka, primary, Schreck, Karisa C., additional, Hu, Chen, additional, Douville, Christopher Blair, additional, Santa-Maria, Cesar Augusto, additional, Connolly, Roisin M, additional, Holdhoff, Matthias, additional, Lipson, Evan J., additional, Parkinson, Rose, additional, Riemer, Joanne, additional, Barnes, Amanda, additional, Venkatesan, Arun, additional, Bettegowda, Chetan, additional, Grossman, Stuart A., additional, and Brahmer, Julie R., additional

Published
2020
Full Text
View/download PDF

192. Abstract B13: Development of a low-cost method for collecting fecal samples in clinical trials

Author

Peloza, Kimberly E., primary, Gills, Joell J., additional, Shaikh, Fyza Y., additional, White, James R., additional, Glass, Sara, additional, Lansiquot, Carisse, additional, Stevens, Courtney, additional, Assan, William, additional, Sharfman, William H., additional, Le, Dung T., additional, Naidoo, Jarushka, additional, Lipson, Evan J., additional, Pardoll, Drew M., additional, and Sears, Cynthia L., additional

Published
2020
Full Text
View/download PDF

194. Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer

Author

Zhang, Jiajia, primary, Ji, Zhicheng, additional, Caushi, Justina X., additional, El Asmar, Margueritta, additional, Anagnostou, Valsamo, additional, Cottrell, Tricia R., additional, Chan, Hok Yee, additional, Suri, Prerna, additional, Guo, Haidan, additional, Merghoub, Taha, additional, Chaft, Jamie E., additional, Reuss, Joshua E., additional, Tam, Ada J., additional, Blosser, Richard L., additional, Abu-Akeel, Mohsen, additional, Sidhom, John-William, additional, Zhao, Ni, additional, Ha, Jinny S., additional, Jones, David R., additional, Marrone, Kristen A., additional, Naidoo, Jarushka, additional, Gabrielson, Edward, additional, Taube, Janis M., additional, Velculescu, Victor E., additional, Brahmer, Julie R., additional, Housseau, Franck, additional, Hellmann, Matthew D., additional, Forde, Patrick M., additional, Pardoll, Drew M., additional, Ji, Hongkai, additional, and Smith, Kellie N., additional

Published
2020
Full Text
View/download PDF

195. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

Author

Thompson, John A., primary, Schneider, Bryan J., additional, Brahmer, Julie, additional, Andrews, Stephanie, additional, Armand, Philippe, additional, Bhatia, Shailender, additional, Budde, Lihua E., additional, Costa, Luciano, additional, Davies, Marianne, additional, Dunnington, David, additional, Ernstoff, Marc S., additional, Frigault, Matthew, additional, Kaffenberger, Benjamin H., additional, Lunning, Matthew, additional, McGettigan, Suzanne, additional, McPherson, Jordan, additional, Mohindra, Nisha A., additional, Naidoo, Jarushka, additional, Olszanski, Anthony J., additional, Oluwole, Olalekan, additional, Patel, Sandip P., additional, Pennell, Nathan, additional, Reddy, Sunil, additional, Ryder, Mabel, additional, Santomasso, Bianca, additional, Shofer, Scott, additional, Sosman, Jeffrey A., additional, Wang, Yinghong, additional, Weight, Ryan M., additional, Johnson-Chilla, Alyse, additional, Zuccarino-Catania, Griselda, additional, and Engh, Anita, additional

Published
2020
Full Text
View/download PDF

196. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Author

Abu-Sbeih, Hamzah, primary, Faleck, David M., additional, Ricciuti, Biagio, additional, Mendelsohn, Robin B., additional, Naqash, Abdul R., additional, Cohen, Justine V., additional, Sellers, Maclean C., additional, Balaji, Aanika, additional, Ben-Betzalel, Guy, additional, Hajir, Ibraheim, additional, Zhang, Jiajia, additional, Awad, Mark M., additional, Leonardi, Giulia C., additional, Johnson, Douglas B., additional, Pinato, David J., additional, Owen, Dwight H., additional, Weiss, Sarah A., additional, Lamberti, Giuseppe, additional, Lythgoe, Mark P., additional, Manuzzi, Lisa, additional, Arnold, Christina, additional, Qiao, Wei, additional, Naidoo, Jarushka, additional, Markel, Gal, additional, Powell, Nick, additional, Yeung, Sai-Ching J., additional, Sharon, Elad, additional, Dougan, Michael, additional, and Wang, Yinghong, additional

Published
2020
Full Text
View/download PDF

197. First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).

Author

Wainberg, Zev A., primary, Diamond, Jennifer Robinson, additional, Curigliano, Giuseppe, additional, Deva, Sanjeev, additional, Bendell, Johanna C., additional, Han, Sae-Won, additional, Kalyan, Aparna, additional, Naidoo, Jarushka, additional, Kim, Richard D., additional, Patel, Sandip Pravin, additional, Kourtesis, Panagiotis, additional, Li, Xia, additional, Ascierto, Maria, additional, Song, Xuyang, additional, Das, Mayukh, additional, and Segal, Neil Howard, additional

Published
2020
Full Text
View/download PDF

198. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer

Author

Anagnostou, Valsamo, primary, Niknafs, Noushin, additional, Marrone, Kristen, additional, Bruhm, Daniel C., additional, White, James R., additional, Naidoo, Jarushka, additional, Hummelink, Karlijn, additional, Monkhorst, Kim, additional, Lalezari, Ferry, additional, Lanis, Mara, additional, Rosner, Samuel, additional, Reuss, Joshua E., additional, Smith, Kellie N., additional, Adleff, Vilmos, additional, Rodgers, Kristen, additional, Belcaid, Zineb, additional, Rhymee, Lamia, additional, Levy, Benjamin, additional, Feliciano, Josephine, additional, Hann, Christine L., additional, Ettinger, David S., additional, Georgiades, Christos, additional, Verde, Franco, additional, Illei, Peter, additional, Li, Qing Kay, additional, Baras, Alexander S., additional, Gabrielson, Edward, additional, Brock, Malcolm V., additional, Karchin, Rachel, additional, Pardoll, Drew M., additional, Baylin, Stephen B., additional, Brahmer, Julie R., additional, Scharpf, Robert B., additional, Forde, Patrick M., additional, and Velculescu, Victor E., additional

Published
2020
Full Text
View/download PDF

199. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Author

Abu-Sbeih, Hamzah, primary, Ali, Faisal S., additional, Naqash, Abdul Rafeh, additional, Owen, Dwight H., additional, Patel, Sandipkumar, additional, Otterson, Gregory A., additional, Kendra, Kari, additional, Ricciuti, Biagio, additional, Chiari, Rita, additional, De Giglio, Andrea, additional, Sleiman, Joseph, additional, Funchain, Pauline, additional, Wills, Beatriz, additional, Zhang, Jiajia, additional, Naidoo, Jarushka, additional, Philpott, Jessica, additional, Gao, Jianjun, additional, Subudhi, Sumit K., additional, and Wang, Yinghong, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results